Borders-based biotech company ProStrakan
halved its losses in 2005 despite increased spending linked to its rapid growth
through expansion in recent years. The firm, which floated on the London market
in June of last year, separately announced its acquisition of the UK rights forTabphyn
for an undisclosed sum.